Mariner
ALXN

Mariner’s Alexion Pharmaceuticals ALXN Stock Holding History

Mariner’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-7,931
Closed -$1.04M – 1100
2019
Q2 		$1.04M Buy
7,931
+213
+3% +$27.5K 0.01% 529
2019
Q1 		$1.04M Buy
7,718
+3,246
+73% +$404K 0.01% 485
2018
Q4 		$435K Sell
4,472
-758
-14% -$89.6K 0.01% 602
2018
Q3 		$727K Sell
5,230
-969
-16% -$122K 0.02% 490
2018
Q2 		$770K Buy
+6,199
New +$724K 0.02% 457
2018
Q1 		– Sell
-4,813
Closed -$576K – 705
2017
Q4 		$576K Buy
4,813
+113
+2% +$13.8K 0.02% 373
2017
Q3 		$659K Sell
4,700
-373
-7% -$50.7K 0.03% 304
2017
Q2 		$617K Sell
5,073
-278
-5% -$32.4K 0.03% 307
2017
Q1 		$649K Sell
5,351
-846
-14% -$109K 0.03% 342
2016
Q4 		$758K Buy
6,197
+372
+6% +$45.5K 0.03% 305
2016
Q3 		$714K Buy
5,825
+135
+2% +$17.4K 0.03% 308
2016
Q2 		$664K Sell
5,690
-4,378
-43% -$621K 0.04% 290
2016
Q1 		$1.4M Buy
10,068
+1,508
+18% +$221K 0.08% 199
2015
Q4 		$1.63M Sell
8,560
-3,115
-27% -$544K 0.1% 165
2015
Q3 		$1.83M Buy
11,675
+415
+4% +$75.7K 0.08% 177
2015
Q2 		$2.04M Buy
11,260
+1,476
+15% +$255K 0.09% 176
2015
Q1 		$1.7M Buy
9,784
+2,150
+28% +$389K 0.14% 121
2014
Q4 		$1.41M Sell
7,634
-1,354
-15% -$251K 0.13% 141
2014
Q3 		$1.49M Buy
8,988
+115
+1% +$18.9K 0.17% 110
2014
Q2 		$1.39M Buy
8,873
+2,838
+47% +$448K 0.15% 125
2014
Q1 		$918K Buy
6,035
+645
+12% +$103K 0.12% 158
2013
Q4 		$716K Buy
5,390
+2,085
+63% +$250K 0.09% 183
2013
Q3 		$384K Buy
+3,305
New +$363K 0.07% 213

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Mariner's ALXN Position: Q3 2019 in Review

Mariner sold out of Alexion Pharmaceuticals (ALXN) in Q3 2019, closing a stake of 7,931 shares — an estimated $1.04M sold.

Mariner first reported a position in ALXN in Q3 2013 and held it in 23 quarters. The position peaked at $2.04M in Q2 2015. 648 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

  • Mariner reported no remaining Alexion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Mariner sold 7,931 Alexion Pharmaceuticals shares in Q3 2019, an estimated $1.04M.
  • Mariner first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 23 quarters.
  • Mariner's Alexion Pharmaceuticals position peaked at $2.04M in Q2 2015.
  • 648 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Mariner's 13F filing for Q3 2019, filed 13 Nov 2019.